Index to Volume 8

Author Index

– B –

Baker MI, Oleen MA: The use of benzodiazepine hypnotics in the elderly, 241
Barriere SL: Commentary on ciprofloxacin, 32
Barriere SL: *see* Jaresko GS, et al, 324
Beck CL, Pucino F, Carlson JD, Silbergleit IL, Strommen GL, Fenelon JC, Lipp R, Gill DS: Evaluation of creatinine clearance estimation in an elderly male population, 183
Beck CL: *see* Strommen GL, et al, 52
Bergman K: *see* Melby MJ, et al, 69
Berner S: *see* Salem DN, et al, 319
Bottorff MB: *see* Hoon TJ, et al, 82
Bowers LD: *see* Cipolle RJ, et al, 47
Brunneman SR: *see* Segal JL, et al, 79
Bushnell MC: *see* Dupuis R, et al, 193
Bussey HI, Hawkins DW, Gaspard JJ, Walsh RA: A comparative trial of digoxin and digitoxin in the treatment of congestive heart failure, 235

– C –

Canafax DM: *see* Cipolle RJ, et al, 47
Carlson JD: *see* Beck CL, et al, 183
Cipolle RJ, Canafax DM, Rabatin J, Bowers LD, Sutherland DER, Hrushesky JM: Time-dependent disposition of cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve immunosuppression, 47
Creger RJ: *see* Danziger LH, et al, 315
Cunha BA: Aminoglycosides: current role in antimicrobial therapy, 334

– D –

Danziger LH, Creger RJ, Shwed JA, Stellato TA, Hau T: Randomized trial of imipenem-cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections, 315
Deterding J: *see* Kandrotas RJ, et al, 351
Dougherty SH: Infections in the bionic man, 7S
Drew RH, Gallis HA: Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application, 35
Drew RH: Ode to the fluoroquinolones, 46
Drusano GL: Commentary on ciprofloxacin, 33
Duncan GH: *see* Dupuis R, et al, 193
Dupuis R, Lemay H, Bushnell MC, Duncan GH: Preoperative flurbiprofen in oral surgery: a method of choice in controlling pain, 193

– E –

Eichorn EJ: *see* Salem DN, et al, 319
Eltorai IM: *see* Segal JL, et al, 79

– F –

Fallot PL: *see* Salva KM, et al, 94
Fenelon JC: *see* Beck CL, et al, 183
Fiedler VB: Role of arachidonic acid metabolites in cardiac ischemia and reperfusion injury, 158
Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F: Nicotinic acid: a review of its clinical use in the treatment of lipid disorders, 287
Figge J: *see* Figge HL, et al, 287
Frishman WH: *see* Murthy VS, et al, 168
Furio MM, Weidle PJ, Wordell CJ, Liu HH: Management of Pneumocystis carinii pneumonia in patients with AIDS and other conditions: experience in a Philadelphia university teaching hospital, 221

– G –

Gallis HA: *see* Drew RH, et al, 35
Garrison MW: *see* Rotschafer JC, et al, 211
Gaspard JJ: *see* Bussey HI, et al, 235
Gill DS: *see* Beck CL, et al, 183
Gordon SK: *see* Segal JL, et al, 79
Greene WL: *see* Hoon TJ, et al, 82
Greer C: Afghan horsemen photo, 220
Gustafsson I: *see* Nystrom E, et al, 201

– H –

Haltom JR: *see* Hill M, et al, 277
Harman E: *see* Massey KL, et al, 189
Hau T: *see* Danziger LH, et al, 315
Hawkins DW: *see* Bussey HI, et al, 235
Hendeles L: *see* Massey KL, et al, 189
Hill M, Haltom JR, Szefler SJ: The consistency of theophylline absorption from a sustained-release formulation in asthmatic children, 277
Hoon TJ, Wood CA, Whidden MA, Greene WL, Bottorff MB: The relative predictive performance of two theophylline pharmcokinetic dosing programs, 82
Hrushesky JM: *see* Cipolle RJ, et al, 47

– J –

Jann MW: Buspirone: an update on a unique anxiolytic agent, 100
Jaresko GS, Barriere SL: Imipenem monotherapy versus combination therapy in the management of mixed bacterial infection: a critical appraisal, 324

– K –

Kandrotas RJ, Deterding J: Genital necrosis secondary to warfarin therapy, 351
Kelly KL: The accuracy and reliability of tests for drugs of abuse in urine samples, 263
Kernodles DS: Surgical prophylaxis: how far have we really come?, 11S
Kim HC: *see* Salva KM, et al, 94
Konstam MA: *see* Salem DN, et al, 319

– L –

Lake KD, Peterson CD: Evaluation of a method for initiating vancomycin therapy: experience in 205 patients, 284
Lam M: Chinese fishermen photo, 88
Lam YWF: Stereoselectivity: an issue of significant importance in clinical pharmacology, 147
Lampert S: *see* Tordjman T, et al, 89
Lampert S: *see* Tordjman T, et al, 295
LeBel M: Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions, 3
Lemay H: *see* Dupuis R, et al, 193
Lipp R: *see* Beck CL, et al, 183
Liu HH: *see* Furio MM, et al, 221
Lobeck F: A review of lithium dosing methods, 248
Lown B: *see* Tordjman T, et al, 89
Lown B: *see* Tordjman T, et al, 295

– M –

Mackey W: *see* Melby MJ, et al, 69
Mann HJ, Steiner JF, Willett MS: ACCP Official Position Statement: Drug use in the elderly, 355
Massey KL, Harman E, Hendeles L: Duration of effect of gallopamil, a calcium channel blocker, on methacholine-induced bronchoconstriction, 189
Melby MJ, Bergman K, Ramos T, Reinhold R, Mackey W: Acute adrenal insufficiency mimicking septic shock: a case report, 69
Murthy VS, Frishman WH: Controlled beta-receptor blockade with esmolol and flestolol, 168
Mutnick AH: *see* Figge HL, et al, 287

– N –

Nahum K: *see* Salva KM, et al, 94
Nystrom E, Gustafsson I, Quiding H: The pain intensity at analgesic intake, and the efficacy of diflunisal in single doses and effervescent acetaminophen in single and repeated doses, 201

– O –

Oleen MA: *see* Baker MI, et al, 241

– P –

Peterson CD: *see* Lake KD, et al, 284
Plotkin MJ: Conservation, ethnobotany, and the search for new jungle medicines: pharmacognosy comes of age . . . again, 257
Pucino F: *see* Strommen GL, et al, 52
Pucino F: *see* Beck CL, et al, 183

– Q –

Quiding H: *see* Nystrom E, et al, 201

– R –

Rabatin J: *see* Cipolle RJ, et al, 47
Raeder E: *see* Tordjman T, et al, 295
Ramos T: *see* Melby MJ, et al, 69
Rapp, RP: Commentary on ciprofloxacin, 30
Reinhold R: *see* Melby MJ, et al, 69
Rodvold KA: *see* Rotschafer JC: et al, 211
Rodvold KA: Therapeutic considerations for infections caused by Staphylococcus epidermidis, 14S
Rotschafer JC, Garrison MW, Rodvold KA: Therapeutic update on glycopeptide and lipopeptide antibiotics, 211
Rotschafer JC: Preface to resistant staphylococci supplement, 1S

– S –

Sacks F: *see* Figge HL, et al, 287
Salem DN, Berner S, Eichorn EJ, Sherman L, Konstam MA: Digitalis therapy for congestive heart failure: is the jury still out?, 319
Salva KM, Kim HC, Nahum K, Fallot PL: DDAVP in the treatment of bleeding disorders, 94
Scheife RT: Ringtail lemur photo, 34
Scheife RT: Singapore market photo, 188
Scheife RT: Bali roosters photo, 276
Segal JL, Brunnemann SR, Gordon SK, Eltorai IM: Amikacin pharmacokinetics in patients with spinal cord injury, 79
Sherman L: *see* Salem DN, et al, 319
Shwed JA: *see* Danziger LH, et al, 315
Silbergleit IL: *see* Beck CL, et al, 183
Souney PF: *see* Figge HL, et al, 287
Stein GE: Commentary on ciprofloxacin, 30
Stein GE: The 4-quinolone antibiotics: past, present, and future, 301
Steiner JF: *see* Mann HJ, et al, 355
Stellato TA: *see* Danziger LH, et al, 315
Strommen GL, Pucino F, Tight RR, Beck CL: Human infection with Herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment, 52
Strommen GL: *see* Beck CL, et al, 183
Sutherland DER: *see* Cipolle RJ, et al, 47
Szefler SJ: *see* Hill M, et al, 277

– T –

Tight RR: *see* Strommen GL, et al, 52
Tordjman T, Lampert S, Lown B: The effect of intracoronary lidocaine infusion on acetylstrophanthidin-induced ventricular arrhythmia in dogs, 89
Tordjman T, Raeder E, Lampert S, Lown B: The effect of intracoronary lidocaine on ventricular arrhythmia in the infarcted canine heart, 295

– W –

Walsh RA: *see* Bussey HI, et al, 235
Weidle PJ: *see* Furio MM, et al, 221
Whidden MA: *see* Hoon TJ, et al, 82
Willett MS: see Mann HJ, et al, 355
Williams TW Jr: The changing susceptibility of staphylococci, 2S
Wood CA: *see* Hoon TJ, et al, 82
Wordell CJ: *see* Furio MM, et al, 221

Subject Index

– A –

Abstracts of ACCP annual meeting, 118
Abuse, drugs, accuracy and reliability of urine tests for, 263
ACCP annual meeting, abstracts from, 118
ACCP Official Position Statement, Drug use in the elderly, 355
ACCP Official Position Statement, Guidelines for clinical fellowship training programs, 299
Acetaminophen, effervescent, efficacy of single and repeated doses vs single doses of diflunisal, 201
Acetylstrophanthidin-induced ventricular arrhythmia, effect of intracoronary lidocaine in dogs, 89
Adrenal insufficiency, acute, mimicking septic shock (case report), 69
Amikacin, current role in antimicrobial therapy, 334
Amikacin, pharmacokinetics in patients with spinal cord injury, 79
Aminoglycosides, current role in antimicrobial therapy, 334
Arachidonic acid metabolites, role in cardiac ischemia and reperfusion injury, 158
Asthmatic children, consistency of theophylline absorption from a sustained-release formulation in, 277

– B –

Benzodiazepine hypnotics, use of in the elderly, 241
Beta-receptor blockade, controlled, with esmolol and flestolol, 168
Bleeding disorders, treatment with DDAVP, 94
Buspirone, pharmacology, clinical use, toxicology, 100

– C –

Cardiac ischemia and reperfusion injury, role of arachidonic acid metabolites in, 158
Chronopharmacokinetics, application of to cyclosporine disposition after pancreas transplantation, 47
Ciprofloxacin, clinical trials, 16; adverse reactions, 21; history, 3; chemistry, mechanism of action, resistance, 5; spectrum, 6; pharmacokinetics, 9
Clindamycin plus gentamicin, vs imipenem-cilastatin in the treatment of polymicrobial infections, 315
Clinical fellowship training programs, guideline for, ACCP Official Position Statement on, 299
Combination antimicrobial therapy, vs imipenem monotherapy in the management of mixed bacterial infection: a critical appraisal, 324
Congestive heart failure, use of digitalis in, is the jury still out?, 319
Conservation, ethnobotany and new jungle medicines, 257
Creatinine clearance estimation, evaluation of in an elderly male population, 183
Cyclosporine, time-dependent disposition of after pancreas transplantation, application of chronopharmacokinetics, 47

– D –

DDAVP, in the treatment of bleeding disorders, 94
Daptomycin, *see* glycopeptide and lipopeptide antibiotics, 211
Desamino arginine vasopressin, *see* DDAVP, 94
Desmopressin, *see* DDAVP, 94
Diflunisal, efficacy of vs effervescent acetaminophen in single and repeated doses, 201
Digitalis, in congestive heart failure: is the jury still out?, 319
Digitoxin, vs digoxin in the treatment of congestive heart failure, 235
Digoxin, vs digitoxin in the treatment of congestive heart failure, 235
Drug use in the elderly, ACCP Official Position Statement on, 355
Drugs of abuse, accuracy and reliability of urine tests for, 263

– E –

Elderly, drug use in, ACCP Official Position Statement on, 355
Esmolol, controlled beta-receptor blockade with, 168
Ethnobotany, conservation and new jungle medicines, 257

– F –

Flestolol, controlled beta-receptor blockade with, 168
Fluoroquinolones, review of entire class, 301; ofloxacin, 35; ciprofloxacin, 3; poem "Ode to the fluoroquinolones", 46
Flurbiprofen, preoperative in oral surgery, method of choice in controlling postoperative pain, 193

– G –

Gallopamil, duration of effect on methacholine-induced bronchoconstriction, 189
Genital necrosis, secondary to warfarin therapy, 351
Gentamicin plus clindamycin, vs imipenem-cilastatin in the treatment of polymicrobial infections, 315
Gentamicin, current role in antimicrobial therapy, 334
Glycocalyx production, importance in infections caused by Staphylococcus epidermidis, 19S
Glycopeptide and lipopeptide antibiotics, therapeutic update on, 211

– H –

Herpes zoster, human infection with, clinical manifestations, 52; human infection with, diagnosis, management, 55
Hypnotics, benzodiazepine, use of in the elderly, 241

– I –

Imipenem-cilastatin, vs gentamicin plus clindamycin in the treatment of polymicrobial infections, 315
Imipenem-cilastatin, monotherapy with vs combination therapy for mixed bacterial infection: a critical appraisal, 324
Implanted devices, infections involving, 7S
Intracoronary lidocaine, effect on ventricular arrhythmia in the infarcted canine heart, 295

– L –

Lidocaine, intracoronary, effect on ventricular arrhythmia in the infarcted canine heart, 295
Lidocaine, intracoronary, effect on acetylstrophanthidin-induced ventricular arrhythmia in dogs, 89
Lipid disorders, use of nicotinic acid in the treatment of, 287
Lipopeptide and glycopeptide antibiotics, therapeutic update on, 211
Lithium, review of dosing methods, 248

– M –

Methacholine-induced bronchoconstriction, duration of effect of gallopamil on, 189

– N –

Necrosis, genital, secondary to warfarin therapy, 351
Niacin, *see* nicotinic acid, 287
Nicotinic acid, in the treatment of lipid disorders, 287

– O –

Ofloxacin, history, 35; chemistry, mechanism of activity & resistance, 36; in vitro activity, 37; pharmacokinetics, 38; clinical trials, 39; adverse effects, 42; interactions, dosage, potential clinical uses, 43

– P –

Pharmacognosy, ethnobotany, conservation, and new jungle medicines, 257
Pneumocystis carinii pneumonia, management of in patients with and without AIDS, 221
Pneumonia, Pneumocystis carinii, management of in patients with and without AIDS, 221
Postoperative dental pain, preoperative flurbiprofen, method of choice to control, 193
Prosthetic devices, infections involving, 7S

– Q –

Quinolone antibiotics, review of, 301

– R –

Red neck syndrome, mechanism, presentation, prevention of, 22S

– S –

Septic shock, acute adrenal insufficiency mimicking (case report), 69
Spinal cord injury, pharmacokinetics of amikacin in patients with, 79
Staphylococci, the changing susceptibility of, 2S
Staphylococcus epidermidis, therapeutic considerations for infections caused by, 14S; overcoming resistance of, 19S; importance of glycocalyx production, 19S
Stereochemistry, *see* stereoselectivity in clinical pharmacology, 147
Stereoselectivity, importance in clinical pharmacology, 147
Surgical prophylaxis, how far have we really come?, 11S

– T –

Teicoplanin, *see* glycopeptide and lipopeptide antibiotics, 211
Theophylline absorption, consistency of from a sustained-release formulation in asthmatic children, 277
Theophylline, the relative predictive performance of two pharmacokinetic dosing programs, 82
Tobramycin, current role in antimicrobial therapy, 334

– V –

Vancomycin, *see* glycopeptide and lipopeptide antibiotics, 211
Vancomycin, use in neonates and children, 23S
Vancomycin, evaluation of a method for initiating therapy with, 284

– W –

Warfarin, genital necrosis secondary to, 351